Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention

[1]  G. D. De Keulenaer,et al.  Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. , 2013, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[2]  J. Baselga,et al.  Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Henk-Jan Guchelaar,et al.  Liposomal drug formulations in cancer therapy: 15 years along the road. , 2012, Drug discovery today.

[4]  S. Cosimo,et al.  Heart to heart with trastuzumab: a review on cardiac toxicity , 2011, Targeted Oncology.

[5]  D. Noonan,et al.  Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. , 2011, Future cardiology.

[6]  A. Zambelli,et al.  Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. , 2011, Breast.

[7]  S. Yusuf,et al.  Radiation-Induced Heart Disease: A Clinical Update , 2011, Cardiology research and practice.

[8]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Lipshultz,et al.  Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer , 2011, Pediatric Cardiology.

[10]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[11]  P. Macdonald,et al.  Parenteral administration of recombinant human neuregulin‐1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses , 2011, European journal of heart failure.

[12]  C. Lestuzzi.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management. , 2010, World journal of cardiology.

[13]  C. Lim,et al.  Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? , 2010, Progress in cardiovascular diseases.

[14]  M. Minami,et al.  Cardiovascular side-effects of modern cancer therapy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[15]  Michael S. Ewer,et al.  Cardiotoxicity of anticancer treatments: what the cardiologist needs to know , 2010, Nature Reviews Cardiology.

[16]  Sean M. O'Brien,et al.  Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. , 2010, The Annals of thoracic surgery.

[17]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[18]  G. Boriani,et al.  Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. , 2010, Pharmacology & therapeutics.

[19]  João Ferreira-Martins,et al.  Anthracycline Cardiomyopathy Is Mediated by Depletion of the Cardiac Stem Cell Pool and Is Rescued by Restoration of Progenitor Cell Function , 2010, Circulation.

[20]  S. De Flora,et al.  Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.

[21]  A. Curtis,et al.  Introducing a new entity: chemotherapy-induced arrhythmia. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[22]  M. Damasceno,et al.  [Cost of cancer care in Portugal]. , 2009, Acta medica portuguesa.

[23]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[24]  D. Khayat,et al.  Management of hypertension in angiogenesis inhibitor-treated patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Glück,et al.  A woman's heart , 2009, Cancer.

[26]  B. Giardina,et al.  New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.

[27]  E. D. de Vries,et al.  Cardiovascular toxicity caused by cancer treatment: strategies for early detection. , 2009, The Lancet. Oncology.

[28]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[29]  S. Glück,et al.  XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer , 2008, International journal of medical sciences.

[30]  R. Prescott,et al.  Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Glück,et al.  Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? , 2008, Clinical advances in hematology & oncology : H&O.

[32]  Ralf Kettenhofen,et al.  Preclinical assessment of cardiac toxicity. , 2008, Drug discovery today.

[33]  P. Viale,et al.  Cardiovascular toxicity associated with cancer treatment. , 2008, Clinical journal of oncology nursing.

[34]  A. Roach,et al.  Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery , 2008, British journal of pharmacology.

[35]  S. Bacus,et al.  Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells , 2008, Cell cycle.

[36]  Charles E. Geyer,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer , 2008 .

[37]  R. Chari.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[38]  E. Schiffrin,et al.  New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone , 2008, Journal of Molecular Medicine.

[39]  James B. Seward,et al.  Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. , 2008, Journal of the American College of Cardiology.

[40]  J. Steinberger,et al.  Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group , 2008, Pediatrics.

[41]  G. D. De Keulenaer,et al.  Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure , 2007, Circulation.

[42]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[43]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[44]  S. Hunt,et al.  Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Syrios,et al.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study , 2007, Journal of Cancer Research and Clinical Oncology.

[46]  Y. Yarden,et al.  Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells , 2007, Proceedings of the National Academy of Sciences.

[47]  C. Sessa,et al.  Ongoing phase I and II studies of novel anthracyclines , 2007, Cardiovascular Toxicology.

[48]  H. Cortés-Funes,et al.  Role of anthracyclines in the era of targeted therapy , 2007, Cardiovascular Toxicology.

[49]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[50]  D. J. Veldhuisen,et al.  Serum HER2 levels are increased in patients with chronic heart failure , 2007, European journal of heart failure.

[51]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[52]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  F. Kratz,et al.  Prodrugs of anthracyclines in cancer chemotherapy. , 2006, Current medicinal chemistry.

[55]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[56]  P. Malmström,et al.  TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer , 2006, Acta oncologica.

[57]  U. Walker,et al.  Tissue‐specific mtDNA lesions and radical‐associated mitochondrial dysfunction in human hearts exposed to doxorubicin , 2005, The Journal of pathology.

[58]  S. Lipshultz,et al.  Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies , 2005, British journal of haematology.

[59]  V. Valero,et al.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[61]  S. Lippman,et al.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Deitcher,et al.  The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma , 2004, Cancer.

[64]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[65]  Xinxin Guo,et al.  Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes* , 2004, Journal of Biological Chemistry.

[66]  K. Kelly,et al.  Antioxidants and cancer therapy: a systematic review. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  P. Mehta.  Thalidomide and thrombosis. , 2003, Clinical advances in hematology & oncology : H&O.

[68]  J. Liao,et al.  NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. , 2003, Journal of molecular and cellular cardiology.

[69]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[70]  E. Winer,et al.  2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D. Larsimont,et al.  HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[72]  Susumu Minamisawa,et al.  ErbB2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Medicine.

[73]  C. Hudis,et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  J. Pérez-Herrero,et al.  Cardiotoxicidad por 5-fluorouracilo: ¿isquemia o toxicidad miocárdica? , 2001 .

[75]  R. Ohno,et al.  Prolongation of the QT Interval and Ventricular Tachycardia in Patients Treated with Arsenic Trioxide for Acute Promyelocytic Leukemia , 2000, Annals of Internal Medicine.

[76]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[77]  P. Dombernowsky,et al.  Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  S. Swain,et al.  Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. , 1998, Seminars in oncology.

[79]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[80]  S. Swain,et al.  Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Hung-Yi Wu,et al.  Molecular Mechanisms of Doxorubicin-induced Cardiomyopathy , 1997, The Journal of Biological Chemistry.

[82]  W. Edwards,et al.  Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. , 1996, Human pathology.

[83]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[84]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[85]  M. Fu,et al.  Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. , 1994, International journal of cardiology.

[86]  S L Hancock,et al.  Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. , 1993, JAMA.

[87]  R. Olson,et al.  Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. , 1993, The Journal of clinical investigation.

[88]  R. Olson,et al.  Doxorubicin cardiotoxicity: analysis of prevailing hypotheses , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[89]  L. Kedes,et al.  Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[90]  M. A. Pacciarini,et al.  Idarubicin (4-demethoxydaunorubicin) , 1986, Investigational New Drugs.

[91]  F. Ganzina.  4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. , 1983, Cancer treatment reviews.

[92]  E. Anderson.  Hudson et al. , 1977 .

[93]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[94]  Ana Ludke,et al.  Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. , 2011, Experimental and clinical cardiology.

[95]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[96]  R. Berardi,et al.  Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[97]  P. Sengupta,et al.  Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. , 2009, The oncologist.

[98]  M. Ewer.  The Impact of Adjuvant Endocrine Therapy on Cardiovascular Health , 2009 .

[99]  K. Shen,et al.  Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer , 2008 .

[100]  J. Hirsh.  Risk of thrombosis with lenalidomide and its prevention with aspirin. , 2007, Chest.

[101]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.

[102]  Steven,et al.  ErbB 2 is essential in the prevention of dilated cardiomyopathy , 2002, Nature Reviews Cancer.

[103]  V. Sánchez Sánchez,et al.  [Cardiotoxicity of 5-fluorouracil: ischemia or myocardial toxicity?]. , 2001, Revista clinica espanola.

[104]  P. Voûte,et al.  Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  S. Takahashi,et al.  Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae. , 1998, Japanese journal of pharmacology.

[106]  G. Hortobagyi,et al.  Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma , 1989, Cancer.

[107]  R. Bonow,et al.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. , 1983, Seminars in oncology.